PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy

BACKGROUND: Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limited efficacy of anti-epidermal growth factor receptor (EGFR) therapy. Increased expression and glycosylation of immune checkpoint molecules in tumors are responsible for cetu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yiqi, Gao, Zhenyue, Hu, Ruxin, Wang, Yuqing, Wang, Yuhong, Su, Zheng, Zhang, Xiaoyue, Yang, Jingxuan, Mei, Mei, Ren, Yu, Li, Min, Zhou, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547513/
https://www.ncbi.nlm.nih.gov/pubmed/34697216
http://dx.doi.org/10.1136/jitc-2021-002699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547513/
https://www.ncbi.nlm.nih.gov/pubmed/34697216
http://dx.doi.org/10.1136/jitc-2021-002699

Ejemplares similares